



CLAIMS

1. A compound having the formula **Ia** or **Ib**



(Ia)



(Ib)

wherein:

P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one heteroatom is nitrogen;

R^1 is hydrogen;

R^2 is selected from: C_{1-6} alkyl, cyano, halogen, $(CO)OR^{10}$, and $CONR^{10}R^{11}$;

R^3 is selected from: C_{1-6} alkyl, cyano, nitro, $(CO)OR^4$, $C_{1-6}alkylNR^4R^5$, $OC_{2-6}alkylNR^4R^5$, $CONR^4R^5$, SO_2R^4 , OSO_2R^4 and $(SO_2)NR^4R^5$;

R^4 is selected from: hydrogen, CF_3 and C_{1-6} alkyl;

R^5 is selected from: hydrogen, C_{1-6} alkyl, $C_{1-6}alkylNR^6R^7$ and; wherein R^4 and R^5 may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, (CO)C₁₋₆alkyl, and wherein R⁶ and R⁷ may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;

R⁸ and R⁹ are independently selected from: hydrogen and C₁₋₆alkyl and wherein R⁸ and R⁹ may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S;

R¹⁰ is selected from hydrogen and C₁₋₆alkyl;

R¹¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkylCN, C₀₋₆alkylaryl, C₂₋₆alkylOR⁸, C₁₋₆alkyl(CO)NR⁶R⁷, C₁₋₆alkyl(SO₂)R⁶, C₁₋₆alkyl(SO₂)NR⁶R⁷, C₀₋₆alkylheteroaryl, C₀₋₆alkylC₃₋₆heterocyclic group and C₁₋₆alkylNR⁶R⁷; and wherein any C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl may be substituted by one or more group Z; and wherein any C₀₋₆alkylC₃₋₆heterocyclic group may be substituted by one or more group Y;

Z is selected from halo, C₁₋₆alkyl, C₁₋₆alkoxy, OCF₃ and CF₃;

Y is selected from: oxo, C₂₋₆alkylOR⁸, C₁₋₆alkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl, OR⁸ and C₂₋₆alkylNR⁸R⁹;

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2, 3 or 4;

as a free base or a salt, or a tautomer thereof.

2. A compound according to claim 1, wherein;

P represents a 6-membered heteroaromatic ring containing one heteroatom selected independently from N and O;

R² is selected from: cyano, halogen, (CO)OR¹⁰, and CONR¹⁰R¹¹;

R³ is selected from: cyano, nitro, C₁₋₆alkylNR⁴R⁵, OC₂₋₆alkylNR⁴R⁵, CONR⁴R⁵, and (SO₂)NR⁴R⁵;

5 R⁴ is selected from: hydrogen and C₁₋₆alkyl;

R⁵ is selected from: C₁₋₆alkyl and C₁₋₆alkylNR⁶R⁷ and; wherein R⁴ and R⁵ may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms selected
10 independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

R⁶ and R⁷ are independently selected from hydrogen, (CO)C₁₋₆alkyl, and wherein R⁶ and R⁷ may together form a 5- or 6-membered heterocyclic group containing one or more
15 heteroatoms, selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

R⁸ and R⁹ are independently selected from: hydrogen and C₁₋₆alkyl and wherein R⁸ and R⁹ may together form a 5- or 6-membered heterocyclic group containing one or more
20 heteroatoms, selected independently from N and O;

R¹⁰ is selected from hydrogen and C₁₋₆alkyl;

R¹¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkylCN, C₀₋₆alkylaryl, C₂₋₆alkylOR⁸, C₁₋₆alkyl(CO)NR⁶R⁷, C₁₋₆alkyl(SO₂)R⁶, C₁₋₆alkyl(SO₂)NR⁶R⁷, C₀₋₆alkylheteroaryl, C₀₋₆alkylC₃₋₆heterocyclic group and C₁₋₆alkylNR⁶R⁷; and wherein any C₀₋₆alkylaryl may be
25 substituted by one or more group Z;

Z is selected from halo, C₁₋₆alkoxy, OCF₃ and CF₃;

30 Y is selected from: oxo, C₂₋₆alkylOR⁸, C₁₋₆alkyl and C₂₋₆alkylNR⁸R⁹;

m is 1 or 2;

n is 1.

5 3. A compound according to claim 1 or 2, wherein P is pyridine.

4. A compound according to any one of claims 1 to 3, wherein R² is selected from cyano, (CO)OR¹⁰, and CONR¹⁰R¹¹.

10 5. A compound according to claim 1, wherein R² is CONR¹⁰R¹¹ and R¹¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkylCN, C₂₋₆alkylOR⁸, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl; and wherein any C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl may be substituted by one or more group Z and wherein Z is selected from C₁₋₆alkoxy, OCF₃ and CF₃.

15 6. A compound according to any one of claims 1 to 5, wherein R³ is selected from: C₁₋₆alkylNR⁴R⁵, OC₂₋₆alkylNR⁴R⁵, CONR⁴R⁵, and (SO₂)NR⁴R⁵; and wherein R⁴ and R⁵ may together form a 6-membered heterocyclic group containing one or two heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y, and wherein Y may be C₁₋₆alkyl.

20 7. A compound according to any one of claims 1 to 5, wherein R³ is selected from: C₁₋₆alkylNR⁴R⁵, OC₂₋₆alkylNR⁴R⁵, CONR⁴R⁵, and (SO₂)NR⁴R⁵; and R⁵ is C₁₋₆alkylNR⁶R⁷ and wherein R⁶ and R⁷ may together form a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N and O, wherein said heterocyclic group
25 may optionally be substituted by a group Y.

8. A compound according to any one of claims 1 to 5, wherein R³ is C₁₋₆alkylNR⁴R⁵ and wherein R⁴ and R⁵ may together form a 6-membered heterocyclic group containing one or two heteroatoms selected independently from N and O, wherein said heterocyclic group
30 may optionally be substituted by a group Y and wherein Y may be C₁₋₆alkyl or oxo.

9. A compound which is

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile
hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-morpholin-4-ylethyl)nicotinamide
hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-methyl-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide
hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-(dimethylamino)ethyl)-*N*-methylnicotinamide
hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide
hydrochloride;

2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile
hydrochloride;

3-[5-({4-[2-(Dipropylamino)ethyl]piperazin-1-yl}sulfonyl)pyridin-2-yl]-2-hydroxy-1*H*-
indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-morpholin-4-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-
indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-
indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-
carbonitrile hydrochloride;

2-Hydroxy-*N*-(3-methoxypropyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-
1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-
carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-
carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(2-thienylmethyl)-1*H*-indole-5-
carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-*1H*-indole-5-carboxamide hydrochloride;

N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*1H*-indole-5-carboxamide hydrochloride;

5 2-Hydroxy-*N*-(2-methoxybenzyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethyl)benzyl]-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethyl)benzyl]-*1H*-
10 indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethoxy)benzyl]-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethoxy)benzyl]-*1H*-indole-5-carboxamide hydrochloride;

15 3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-thienylmethyl)-*1H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(pyridin-2-ylmethyl)-*1H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-methoxyethyl)-*1H*-indole-5-
20 carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(tetrahydrofuran-2-ylmethyl)-*1H*-indole-5-carboxamide hydrochloride;

N-Benzyl-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*1H*-indole-5-carboxamide hydrochloride;

25 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-propyl-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-
30 *1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-3-ylmethyl)-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-4-ylmethyl)-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-2-ylmethyl)-*1H*-indole-5-carboxamide hydrochloride;

5 *N*-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-[2-(methylsulfonyl)ethyl]-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*1H*-indole-5-carboxamide hydrochloride;

10 3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-{2-[(4-methylpiperazin-1-yl)sulfonyl]ethyl}-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*1H*-indole-5-sulfonamide hydrochloride;

15 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*1H*-indole-6-carboxamide hydrochloride;

20 3-[5-({4-[2-(Dimethylamino)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-*1H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-(5-nitropyridin-2-yl)-*1H*-indole-5-carboxamide hydrochloride;

N-(2-Cyanoethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*1H*-indole-5-carboxamide hydrochloride;

25 2-Hydroxy-*N*-[2-(*1H*-imidazol-4-yl)ethyl]-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*1H*-indole-5-carboxamide hydrochloride;

N-Benzyl-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*1H*-indole-5-carboxamide hydrochloride;

30 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-propyl-*1H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*1H*-indole-5-carboxamide hydrochloride;

N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide hydrochloride;

5 2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-methyl-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

10 6-Bromo-2-hydroxy-*N*-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-isopropyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

15 6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(tetrahydrofuran-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-pyrrolidin-1-ylethyl)-1*H*-indole-5-carboxamide hydrochloride;

20 *N*-[3-(Dimethylamino)propyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-pyridin-3-yl-1*H*-indole-5-carboxamide hydrochloride;

25 2-Hydroxy-*N*-(2-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(3-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

30 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-*N*-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(Cyanomethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Furylmethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-{5-[(3-oxopiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1*H*-indole-6-carbonitrile hydrochloride;

3-{6-[2-(Diisopropylamino)ethoxy]pyrimidin-4-yl}-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylic acid hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-thienyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Acetylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Cyanoethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(Cyanomethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid carbamoylmethylamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(methylsulfonyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

5 Methyl 3-fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-5-carboxylate hydrochloride;

3-(5-Diethylaminomethyl-pyridin-2-yl)-2-hydroxy-1*H*-indole-5-carboxylic acid (2-methanesulfonyl-ethyl)-amide hydrochloride;

10 as a free base or another salt than hydrochloride, or a tautomer thereof;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

3-(4-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide;

15 2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid (2-carbamoyl-ethyl)amide;

2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid methyl ester;

2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid (thiophen-2-ylmethyl)-amide dihydrochloride;

20 2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid benzylamide dihydrochloride;

as a free base or a salt, or a tautomer thereof.

10. A compound according to claim 9, which is in the form of a pharmaceutically
25 acceptable salt.

11. A compound which is

6-Chloronicotinic acid 1-oxide;

30 Ethyl 6-chloronicotinate 1-oxide;

1-[(6-Chloro-1-oxidopyridin-3-yl)carbonyl]-4-methylpiperazine;

- tert*-Butyl 4-[(6-chloropyridin-3-yl)sulfonyl]piperazine-1-carboxylate ;
(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)dipropylamine;
4-(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)morpholine;
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(2-pyrrolidin-1-ylethyl)piperazine;
5 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(2-methoxyethyl)piperazine;
6-Chloro-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)dimethylamine;
2-Oxo-*N*-(pyridin-2-ylmethyl)indoline-5-carboxamide;
2-Oxo-*N*-(2-thienylmethyl)indoline-5-carboxamide;
10 2-Oxo-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]indoline-5-carboxamide;
N-[2-(Acetylamino)ethyl]-2-oxoindoline-5-carboxamide;
N-(3-Methoxypropyl)-2-oxoindoline-5-carboxamide;
6-Bromo-*N*-isopropyl-2-oxoindoline-5-carboxamide;
6-Bromo-*N*-(2-methoxyethyl)-2-oxoindoline-5-carboxamide;
15 6-Bromo-2-oxo-*N*-(tetrahydrofuran-2-ylmethyl)indoline-5-carboxamide;
6-Bromo-2-oxo-*N*-(2-pyrrolidin-1-ylethyl)indoline-5-carboxamide;
N-[3-(Dimethylamino)propyl]-2-oxoindoline-5-carboxamide;
N-(2-Methoxybenzyl)-2-oxoindoline-5-carboxamide;
N-(3-Methoxybenzyl)-2-oxoindoline-5-carboxamide;
20 *N*-(4-Methoxybenzyl)-2-oxoindoline-5-carboxamide;
2-Oxo-*N*-(tetrahydro-2*H*-pyran-4-yl)indoline-5-carboxamide;
N-Benzyl-2-oxoindoline-5-carboxamide;
N-(2-Methoxyethyl)-2-oxoindoline-5-carboxamide;
2-Oxo-*N*-propylindoline-5-carboxamide;
25 *N*-[2-(Dimethylamino)ethyl]-2-oxoindoline-5-carboxamide;
N-(2-Cyanoethyl)-2-oxoindoline-5-carboxamide;
4-[(6-Chloro-1-oxidopyridin-3-yl)methyl]morpholine;
4-[(6-Chloropyridin-3-yl)sulfonyl]morpholine;
N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-*N*-ethylethanamine;
30 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-methylpiperazine;
1-[(6-chloro-1-oxidopyridine-3-yl)methyl]piperidine;
4-[(6-Chloro-1-oxidopyridin-3-yl)methyl]piperazin-2-one;

N-{2-[(4-Methylpiperazin-1-yl)sulfonyl]ethyl}-2-oxoindoline-5-carboxamide;

4-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}morpholine;

N-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}-*N*-isopropylpropan-2-amine;

Ethyl 6-(6-cyano-2-hydroxy-1*H*-indol-3-yl)nicotinate;

5 Methyl 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxylate;

Methyl 3-{5-[(diethylamino)methyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carboxylate;

Methyl 2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylate;

10 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylic acid;

Methyl 3-(4-cyanopyridin-2-yl)-2-hydroxy-1*H*-indole-5-carboxylate;

as a free base or a salt, or a tautomer thereof.

12. A pharmaceutical formulation comprising as active ingredient a therapeutically
15 effective amount of the compound according to any one of claims 1 to 10 in association with pharmaceutically acceptable carriers or diluents.

13. The pharmaceutical formulation according to claim 12 for use in the prevention and/or
treatment of conditions associated with glycogen synthase kinase-3.

20 14. A compound as defined in any one of claims 1 to 10 for use in therapy.

15. Use of a compound according to any one of claims 1 to 10 in the manufacture of a
medicament for prevention and/or treatment of conditions associated with glycogen
25 synthase kinase-3.

16. Use of a compound according to any one of claims 1 to 10 in the manufacture of a
medicament for prevention and/or treatment of dementia, Alzheimer's Disease,
Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia
30 complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologie and dementia pugilistica.

17. The use according to claim 16 wherein the prevention and/or treatment is for Alzheimer's Disease.

18. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive medication and Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

19. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia.

20. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of bone-related disorders.

21. A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula Ia or Ib as defined in any one of claims 1 to 10.

22. A method of prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, comprising administering to a mammal, including

man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula Ia or Ib as defined in any one of claims 1 to 10.

23. The method according to claim 22, wherein the prevention and/or treatment is for Alzheimer's Disease.


24. A method of prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive medication, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula Ia or Ib as defined in any one of claims 1 to 10.

25. A method of prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula Ia or Ib as defined in any one of claims 1 to 10.

26. A method of prevention and/or treatment of bone-related disorders, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 10.


27. A process for the preparation of a compound of formula Ia according to claim 1, wherein P, R¹, R² and R³, m and n, unless otherwise specified, are defined in claim 1,

comprising reacting a compound of formula A, wherein L^1 is a leaving group, with a compound of formula D to form a compound of formula Ia;




said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.

- 10 28. A process for the preparation of a compound of formula Ia according to claim 1, wherein R^1 , R^2 and R^3 and m , is as defined in claim 1, and halo is halogen, unless otherwise specified, comprising reacting a compound of formula B with a compound of formula D to form a compound of formula Ia;



said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.

29. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^3 is CONR^4R^5 , comprising reacting a compound of formula **XIX**, wherein R^4 is C_{1-6} alkyl, with the appropriate amine HNR^4R^5 , to form a compound of formula **Ia**;



10 said reaction being carried out by;


i) reacting the compound of formula **XIX** with the appropriate amine $\text{R}^4\text{R}^5\text{NH}$ in a suitable solvent in the presence of a suitable reagent at a reaction temperature between 0 °C and reflux or;

15 ii) reacting the compound of formula **XIX** with the appropriate amine $\text{R}^4\text{R}^5\text{NH}$ neat or in a suitable solvent with or without a suitable base or an alkylamine base at a temperature between -20 °C and +150 °C.

30. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^2 is $\text{CONR}^{10}\text{R}^{11}$, comprising amidation of a compound of formula **C**, wherein R^4 is C_{1-6} alkyl, to form a compound of the formula **Ia**;


20

117



said reaction being carried out with the appropriate amine $\text{HNR}^{10}\text{R}^{11}$ in a suitable solvent
 5 in the presence of trimethylaluminum and at a reaction temperature between $-10\text{ }^{\circ}\text{C}$ and
 reflux.


31. A process for the preparation of a compound of formula **Ia** according to claim 1,
 wherein R^2 is $\text{CONR}^{10}\text{R}^{11}$, comprising amidation of a compound of formula **E**, to form a
 10 compound of the formula **Ia**, with the appropriate amine $\text{HNR}^{10}\text{R}^{11}$;



carried out by activation of the acid function in a compound of formula **E** with;
 a) a halogenation reagent in a suitable solvent at a temperature between $0\text{ }^{\circ}\text{C}$ and $+80\text{ }^{\circ}\text{C}$,
 followed by the reaction with the appropriate amine $\text{HNR}^{10}\text{R}^{11}$ in a suitable solvent with or
 without a suitable base at a temperature between $-20\text{ }^{\circ}\text{C}$ and $+80\text{ }^{\circ}\text{C}$, or;

b) a coupling reagent where the reaction is carried out in a suitable solvent at a temperature between +20 °C and +130 °C, followed by addition of the appropriate amine $\text{HNR}^{10}\text{R}^{11}$.

32. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^3 is $\text{C}_{1-6}\text{alkylNR}^4\text{R}^5$, comprising fluorinating a compound of formula **XXIa** to form a compound of formula **Ib**.



said reaction being carried out in an appropriate solvent in the presence of a suitable fluorinating reagent and a suitable base at a reaction temperature between -40 °C and +80 °C.

33. The use of the intermediates according to claim 11 for the preparation of a compound of formula **Ia** or **Ib** as defined in any one of claims 1 to 10.